Newton, C. L.; Hoffman, J. M.; Darke, P. L.; Zugay-Murphy, J. A.;
Emini, E. A.; Schlief, W. A.; Olsen, D. B.; Stahlhut, M. W.;
Rutkowski, C. A.; Kuo, L. C.; Lin, J. H.; Chen, I. W.; Michelson, S.
R.; Holloway, M. K.; Huff, J. R.; Vacca, J. P. J. Med. Chem. 2000, 43,
3386-3399 (b) Bhupathy, M.; Conlon, D. A.; Wells, K. M.; Nelson, J.
R.; Reider, P. J.; Rossen, K.; Sager, J. W.; Volante, R. P.; Dorsey, B.
D.; Hoffman, J. M.; Joseph, S. A.; McDaniel, S. L. J. J. Heterocycl.
Chem. 1995, 32, 1283-1287 (c) Choi, W. B.; Houpis, I. N.; Churchill,
H. R. O.; Molina, A.; Lynch, J. E.; Volante, R. P.; Reider, P. J.; King,
A. O. Tetrahedron Lett. 1995, 36, 4571-4574 (d) Houpis, I. N.; Choi,
W. B.; Reider, P. J.; Molina, A.; Churchill, H.; Lynch, J.; Volante, R.
P. Tetrahedron Lett. 1994, 35, 9355-9358.
(a) Yonishi, S.; Itani, H.; Sato, Y.; Tsutsumi, H.; Akahane, A. PCT
Int. Appl., 2004, WO 2004089939 A1 (b) Toupence, R. B.;
Debenham, J. S.; Goulet, M. T.; Madsen-Duggan, C. B.; Walsh, T. F.;
Shah, S. K. PCT Int. Appl., 2004, WO 2004012671 A2.
VanSickle, A. P.; Rapoport, H. J. Org. Chem. 1990, 55, 895-901.
Malamas, M. S.; Sredy, J.; Moxham, C.; Katz, A.; Xu, W.; McDevitt,
R.; Adebayo, F. O.; Sawicki, D. R.; Seestaller, L.; Sullivan, D.;
Taylor, J. R. J. Med. Chem. 2000, 43, 1293-1310.
In conclusion,
a series of novel furo [2,3-b] pyridine
carboxamide and pyrido [3',2':4,5] furo [3,2-d] pyrimidinone
derivatives were prepared and evaluated for cytotoxicity against
four human cancer cell lines and one normal (non-tumor) cell
line. Among all the compounds screened, the compounds 4e, 4f,
4g, and 5h showed significant activity against all cell lines at
micro molar concentration. A series of novel furo [2,3-b]
pyridine-2-carbohydrazide Schiff’s base & pyrido [3',2':4,5]
furo [3,2-d] pyrimidin-4(3H)-one derivatives were also
evaluated for anticancer activity. The activity results showed
that Schiff’s base derivatives 7a-h showed promising cytotoxic
activity as compared to pyrido furo pyrimidin-4(3H)-one
derivatives 8a-h. Among the promising ones, compounds 7c,
7d, 7e and 7f exhibited potent anticancer activity against five
human cancer cell lines and all compounds screened against
human normal cell line were found to be non-cytotoxic to
normal cell line, HEK-293. 3D-QSAR CoMFA, CoMSIA
studies have been applied to a set of furo [2,3-b] pyridine
carboxamide and pyrido [3',2':4,5] furo[3,2-d] pyrimidinone
derivatives. Both these CoMFA and CoMSIA models for HeLa,
MFC-7 and COLO205 inhibitors generated have confirmed to
be statistically precise with higher q2 and r2. The information
achieved from CoMFA and CoMSIA models could lead to a
better design of novel selective and higher potent furo[2,3-b]
pyridine carboxamide and pyrido [3',2':4,5] furo [3,2-d]
pyrimidinone derivatives as cancer cell line inhibitors
6.
7.
8.
9.
Flynn, B. L.; Chaplin, J. H.; Paul, D.; Grobelny, D. W.; Kelly, B. B.
PCT Int. Appl., 2008, WO 2008070908 A1.
10. Martin, M. W.; Newcomb, J.; Nunes, J. J.; Bemis, J. E.; McGowan, D.
C.; White, R. D.; Buchanan, J. L.; DiMauro, E. F.; Boucher, C.; Faust,
T.; Hsieh, F.; Huang, X.; Lee, J. H.; Schneider, S.; Turci, S. M.; Zhu,
X. Bioorg. Med. Chem. Lett. 2007, 17, 2299-2304.
11. Wu, Z.; Robinson, R. G.; Fu, S.; Barnett, S. F.; Defeo-Jones, D.;
Jones, R. E.; Kral, A. M.; Huber, H. E.; Kohl, N. E.; Hartman, G. D.;
Bilodeau, M. T. Bioorg. Med. Chem. Lett. 2008, 18, 2211-2214.
12. Chabrier, P. E.; Guinot, P. & Tarrade, T. 1988, 6, 166-179.
13. Bukowski, R. D.; Wagman, P.; De Wan. P & Xue, H. Arch Mal Coeur.
1989, 82, 45-50.
14. Singh, V.; Srivastava, V. K.; Palit, G.; Shanker, K. Drug. Res. 1992,
42, 993-996.
15. Angela, M.; Vedrana, C. C.; Nikolina, R. M.; Milena, V. R.; David,
B.; Euphemia, Y. L.; Johannes. R.; Anita M. Drug Design,
Development and Therapy 2017, 11, 759–769.
Acknowledgements
16. Hertel, L. W.; Kroin, J. S.; Misner, J. W.; Tustin, J. M. J. Org. Chem.,
1988, 53, 2406-2409.
17. Filler, R. Studies in Organic Chemistry. 1993, 48, 362.
18. Chae, J.; Konno, T.; Ishihara, T.; Yamanaka, H. Chem. Lett. 2004, 33,
314-315.
19. Narsaiah, B.; Shivaprasad, A.; Venkataratnam, R. V. J. Fluorine
Chem. 1994, 69, 139-143.
20. Abdel-Rahman, E.; Abdul, E.; Bakhite, Etify, A.; Al-Taifi, Elham. A.
J. Chem. Res. 2005, 2005, 461-468.
21. Mosmann, T. J. Immunol. Methods 1983, 65, 55-63.
22. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. J. Am. Chem. Soc. 1988,
110, 5959-5967.
Authors are thankful to the Council of Scientific and Industrial
Research (CSIR), New Delhi, India for the financial assistance
through a XII five year plan project DITSF code:CSC-0204.
Authors (G. Santhosh Kumar Y. Poornachandra, K. Ratnakar
Reddy) are also thankful to CSIR for providing Senior Research
Fellowship and contingency grant.
23. Klebe, G.; Abraham, U.; Mietzner, T. J. Med. Chem. 1994, 37, 4130-
4146.
References and notes:
24. Gasteiger, J.; Marsili, M. Tetrahedron. 1980, 36, 3219-3228.
25. Roy, K. K.; Dixit, A.; Saxena, A. K. J. Mol. Graph. Model. 2008, 27,
197-208.
26. Cramer III, R. D.; Bunce, J. D.; Patterson, D. E. Quant. Struct. Act.
Relat., 1988, 7, 18-25.
1.
Anand, P.; Kunnumakara, A. B.; Sundaram, C.; Harikumar, K. B.;
Tharakan, S. T.; Lai, O. S.; Sung, B.; Aggarwal, B. B. Pharm. Res.
2008, 25, 2097-2116.
Kawakami, K.; Takahashi, H.; Ohki, H.; Kimura, K.; Miyauchi, S.; R.
Miyauchi, M. Takemura, Chem. Pharm. Bull. 2000, 28, 1667-1672.
Ledoossal, B.; Boazard, D.; Coroneos, E. J. Med. Chem. 1992, 35, 198-
200.
Fokialakis, N.; Magiatis, P.; Aligiannis, N.; Mitaku, S.; Tillequin, F.;
Sévenet, T. Phytochemistry. 2001, 57, 593-596.
(a) Dorsey, B. D.; McDonough, C.; McDaniel, S. L.; Levin, R. B.;
2.
3.
4.
5.
10